Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal

Illumina pushed back against Carl Icahn's proxy fight over the Grail deal, saying it's committed to maximizing shareholder value as it works with regulators.

from Health and Science https://ift.tt/FMx8wv3
https://ift.tt/7Tbsc3i
https://ift.tt/wxKli5o